Product news

Share this article:

InSite Vision, an ophthalmic therapeutics, diagnostics and drug delivery company, announced the US launch and commercial availability of AzaSite (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis by Inspire Pharmaceuticals. Inspire said AzaSite has been shipped to pharmacies throughout the US, and Inspire's sales force of 98 sales representatives has begun product education outreach to physicians.

Esprit Pharma has exercised its option to acquire the marketing rights of the recently approved Sanctura XR (trospium chloride extended release capsules). Esprit Pharma paid the milestone due upon approval by the FDA to its development and co-promotion partner, Indevus Pharmaceuticals, securing Esprit rights to market Sanctura XR in the US. Indevus announced on Aug. 6, that Sanctura XR had been approved by the FDA. Sanctura XR is indicated for the once-daily treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

LifeCycle Pharma and Sciele Pharma, announced that LifeCycle Pharma has received FDA approval for LifeCycle Pharma's novel formulation of fenofibrate in 120 mg. and 40 mg. dosage strengths for the treatment of hyperlipidemia and hypertriglyceridemia. This fenofibrate utilizes LifeCycle Pharma's meltdose technology which is designed to provide enhanced absorption and greater bioavailability. Under the terms of the agreement with Sciele, LifeCycle Pharma has already received an up-front payment of $5 million, and will receive a further $4 million milestone payment now that this fenofibrate product has received FDA approval. LifeCycle Pharma will also receive milestone payments of up to $8 million when certain sales targets are met, and tiered royalty payments on product sales. The receipt of $4 million in approval milestone does not change LifeCycle's financial expectations for 2007. This fenofibrate product will have the lowest dosage strengths of fenofibrate available for patients and will be marketed in the US by Sciele Pharma's primary care sales force by the end of 2007. Sciele Pharma currently has approximately 450 primary care sales representatives.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.